Regulation of tumor metastasis by myeloid-derived suppressor cells

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 97-110

  Condamine, Thomas ^a   Ramachandran, Indu ^a   Youn, Je In ^b   Gabrilovich, Dmitry I ^a  

^a WISTAR INSTITUTE   (United States)

^b Seoul National University   (South Korea)

Author keywords

angiogenesis; chemotherapy; immune suppression; tumor cell invasion

Indexed keywords

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CELL EXPANSION; CELL FUNCTION; CELL MIGRATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR INVASION; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

HUMANS; MYELOID CELLS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84921358561     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051013-052304     Document Type: Article

References (97)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253-68
2. Talmadge JE, Gabrilovich DI. 2013. History ofmyeloid-derived suppressor cells. Nat. Rev. Cancer 13:739-52
3. Youn JI, Gabrilovich DI. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40:2969-75
4. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-74
5. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791-802
6. Movahedi K, Guilliams M, Van den Bossche J, et al. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233-44
7. Segal AW. 2005. How neutrophils kill microbes. Annu. Rev. Immunol. 23:197-223
8. Youn JI, Collazo M, Shalova IN, et al. 2012. Characterization of the nature of granulocytic myeloidderived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91:167-81
9. Youn JI, KumarV, Collazo M, et al. 2013. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14:211-20
10. CorzoCA, CondamineT, Lu L, et al. 2010. HIF-1alpha regulates function and differentiation ofmyeloidderived suppressor cells in the tumor microenvironment. J. Exp. Med. 207:2439-53
11. Greten TF, Manns MP, Korangy F. 2011. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11:802-7
12. Brandau S, Trellakis S, Bruderek K, et al. 2011. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89:311-17
13. Rodriguez PC, Ernstoff MS, Hernandez C, et al. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553-60
14. Filipazzi P, Valenti R, Huber V, et al. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients withmodulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25:2546-53
15. Poschke I, Mougiakakos D, Hansson J, et al. 2010. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70:4335-45
16. Poschke I, Kiessling R. 2012. On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 144:250-68
17. Diaz-MonteroCM, SalemML, NishimuraMI, et al. 2009. Increased circulatingmyeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49-59
18. Wang L, Chang EW, Wong SC, et al. 2013. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J. Immunol. 190:794-804
19. Zhang B, Wang Z, Wu L, et al. 2013. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLOS ONE 8:e57114
20. Sun HL, Zhou X, Xue YF, et al. 2012. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol. 18:3303-9
21. Cui TX, Kryczek I, Zhao L, et al. 2013. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39:611-21
22. Khaled Y, Ammori B, Elkord E. 2014. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J. Immunol. Res. 2014:879897
23. Walter S, Weinschenk T, Stenzl A, et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18:1254-61
24. Antonia SJ, Mirza N, Fricke I, et al. 2006. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12:878-87
25. First report describing the effect of MDSC targeting in cancer patients on immune response to vaccines.
26. Iclozan C, Antonia S, Chiappori A, et al. 2013. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 62:909-18
27. Arihara F, Mizukoshi E, Kitahara M, et al. 2013. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 62:1421-30
28. Feng PH, Lee KY, Chang YL, et al. 2012. CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am. J. Respir. Crit. CareMed. 186:1025-36
29. Huang A, Zhang B, Wang B, et al. 2013. Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol. Immunother. 62:1439-51
30. Meyer C, Cagnon L, Costa-Nunes CM, et al. 2014. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63:247-57
31. Condamine T, Gabrilovich DI. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19-25
32. Nefedova Y, Huang M, Kusmartsev S, et al. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:464-74
33. Cheng P, Corzo CA, Luetteke N, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205:2235-49
34. Marigo I, Bosio E, Solito S, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32:790-802
35. Waight JD, Netherby C, Hensen ML, et al. 2013. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123:4464-78
36. Liu Y, Xiang X, Zhuang X, et al. 2010. Contribution ofMyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am. J. Pathol. 176:2490-99
37. Martino A, Badell E, Abadie V, et al. 2010. Mycobacterium bovis bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J. Immunol. 184:2038-47
38. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67:4507-13
39. Zhang Y, Liu Q, Zhang M, et al. 2009. Fas signal promotes lung cancer growth by recruiting myeloidderived suppressor cells via cancer cell-derived PGE2. J. Immunol. 182:3801-8
40. Zhao X, Rong L, Zhao X, et al. 2012.TNFsignaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122:4094-104
41. Nagaraj S, Gupta K, Pisarev V, et al. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828-35
42. Lu T, Ramakrishnan R, Altiok S, et al. 2011. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121:4015-29
43. Rodriguez PC, Zea AH, Culotta KS, et al. 2002. Regulation of T cell receptor CD3zeta chain expression by L-Arginine. J. Biol. Chem. 277:21123-29
44. Zea AH, Rodriguez PC, Atkins MB, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:3044-48
45. Srivastava MK, Sinha P, Clements VK, et al. 2010. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70:68-77
46. Huang B, Pan PY, Li Q, et al. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-31
47. Yang R, Cai Z, Zhang Y, et al. 2006. CD80 in immune suppression by mouse ovarian carcinoma-Associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66:6807-15
48. Pan PY, Ma G, Weber KJ, et al. 2010. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70:99-108
49. Serafini P, Mgebroff S, Noonan K, Borrello I. 2008. Myeloid-derived suppressor cells promote crosstolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439-49
50. Schlecker E, Stojanovic A, Eisen C, et al. 2012. Tumor-infiltrating monocyticmyeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189:5602-11
51. Hoechst B, Gamrekelashvili J, Manns MP, et al. 2011. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117:6532-41
52. Centuori SM, Trad M, LaCasse CJ, et al. 2012. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3-T cells. J. Leukoc. Biol. 92:987-97
53. Novitskiy SV, Pickup MW, Gorska AE, et al. 2011. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov. 1:430-41
54. Hu X, Li B, Li X, et al. 2014. Transmembrane TNF-Alpha promotes suppressive activities of myeloidderived suppressor cells via TNFR2. J. Immunol. 192:1320-31
55. Yu J, Du W, Yan F, et al. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190:3783-97
56. Achberger S, Aldrich W, Tubbs R, et al. 2013. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 58:182-86
57. Weide B, Martens A, Zelba H, et al. 2014. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin. Cancer Res. 20:1601-9
58. Sander LE, Sackett SD, Dierssen U, et al. 2010. Hepatic acute-phase proteins control innate immune responses during infection by promotingmyeloid-derived suppressor cell function. J. Exp.Med. 207:1453-64
59. Acharyya S, Oskarsson T, Vanharanta S, et al. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150:165-78
60. Connolly MK, Mallen-St Clair J, Bedrosian AS, et al. 2010. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-Abdominal tumor. J. Leukoc. Biol. 87:713-25
61. Toh B, Wang X, Keeble J, et al. 2011. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLOS Biol. 9:e1001162
62. Katoh H, Wang D, Daikoku T, et al. 2013. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-Associated tumorigenesis. Cancer Cell 24:631-44
63. Obermajer N, Muthuswamy R, Odunsi K, et al. 2011. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71:7463-70
64. Huang B, Lei Z, Zhao J, et al. 2007. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252:86-92
65. Lesokhin AM, Hohl TM, Kitano S, et al. 2012. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72:876-86
66. Sawanobori Y, Ueha S, Kurachi M, et al. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111:5457-66
67. Molon B, Ugel S, Del Pozzo F, et al. 2011. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208:1949-62
68. Simpson KD, Templeton DJ, Cross JV. 2012. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J. Immunol. 189:5533-40
69. Simpson KD, Cross JV. 2013. MIF: metastasis/MDSC-inducing factor?. Oncoimmunology 2:e23337
70. Sinha P, Okoro C, Foell D, et al. 2008. Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181:4666-75
71. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8:1369-75
72. Ichikawa M, Williams R, Wang L, et al. 2011. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 9:133-48
73. Hiratsuka S, Watanabe A, Sakurai Y, et al. 2008. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10:1349-55
74. Du R, Lu KV, Petritsch C, et al. 2008. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-20
75. Ye XZ, Yu SC, Bian XW. 2010. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J. Genet. Genomics 37:423-30
76. Pan PY, Wang GX, Yin B, et al. 2008. Reversion of immune tolerance in advancedmalignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111:219-28
77. Qu X, Zhuang G, Yu L, et al. 2012. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J. Biol. Chem. 287:19574-84
78. KujawskiM, KortylewskiM, Lee H, et al. 2008. Stat3mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118:3367-77
79. Kowanetz M, Wu X, Lee J, et al. 2010. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA 107:21248-55
80. Shojaei F, Wu X, Zhong C, et al. 2007. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450:825-31
81. Yang L, DeBusk LM, Fukuda K, et al. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-21
82. Priceman SJ, Sung JL, Shaposhnik Z, et al. 2010. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115:1461-71
83. Shojaei F, Wu X, Malik AK, et al. 2007. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25:911-20
84. Finke J, Ko J, Rini B, et al. 2011. MDSC as a mechanism of tumor escape from sunitinib mediated anti-Angiogenic therapy. Int. Immunopharmacol. 11:856-61
85. Yang L, Huang J, Ren X, et al. 2008. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35
86. Boutte AM, Friedman DB, Bogyo M, et al. 2011. Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis. FASEB J. 25:2626-37
87. Kitamura T, Kometani K, Hashida H, et al. 2007. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat. Genet. 39:467-75
88. Pang Y, Gara SK, Achyut BR, et al. 2013. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 3:936-51
89. Oh K, Lee OY, Shon SY, et al. 2013. A mutual activation loop between breast cancer cells and myeloidderived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 15:R79
90. Kuonen F, Laurent J, Secondini C, et al. 2012. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. Clin. Cancer Res. 18:4365-74
91. Sceneay J, Chow MT, Chen A, et al. 2012. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72:3906-11
92. Gao D, Vahdat LT, Wong S, et al. 2012. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 72:4883-89
93. Panni RZ, Sanford DE, Belt BA, et al. 2014. Tumor-induced STAT3 activation in monocytic myeloidderived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother. 63:513-28
94. Yan HH, Pickup M, Pang Y, et al. 2010. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 70:6139-49
95. GaoD, Joshi N, Choi H, et al. 2012. Myeloid progenitor cells in the premetastatic lung promotemetastases by inducing mesenchymal to epithelial transition. Cancer Res. 72:1384-94
96. Sawant A, Deshane J, Jules J, et al. 2013. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 73:672-82
97. Catena R, Bhattacharya N, El Rayes T, et al. 2013. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3:578-89